{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:08:58Z","timestamp":1790762938759,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K09552"],"award-info":[{"award-number":["22K09552"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-21844-3","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:32:43Z","timestamp":1761831163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Hiroyuki","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuji","family":"Rokugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"21844_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"21844_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","volume":"4","author":"KR Cho","year":"2009","unstructured":"Cho, K. R. & Shih, I. E. M. Ovarian cancer. Annu. Rev. Pathol. 4, 287\u2013313 (2009).","journal-title":"Annu. Rev. Pathol."},{"key":"21844_CR3","doi-asserted-by":"publisher","first-page":"x118","DOI":"10.1093\/annonc\/mds315","volume":"23","author":"FA Raja","year":"2012","unstructured":"Raja, F. A., Chopra, N. & Ledermann, J. A. Optimal first-line treatment in ovarian cancer. Ann. Oncol. 23, x118\u2013x127 (2012).","journal-title":"Ann. Oncol."},{"key":"21844_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann, J. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24, 24\u201332 (2013).","journal-title":"Ann. Oncol."},{"key":"21844_CR5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3802\/jgo.2015.26.4.336","volume":"26","author":"SJ Chang","year":"2015","unstructured":"Chang, S. J., Bristow, R. E., Chi, D. S. & Cliby, W. A. Role of aggressive surgical cytoreduction in advanced ovarian cancer. J. Gynecol. Oncol. 26, 336\u2013342 (2015).","journal-title":"J. Gynecol. Oncol."},{"key":"21844_CR6","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1097\/IGC.0000000000001023","volume":"27","author":"N Colombo","year":"2017","unstructured":"Colombo, N., Lorusso, D. & Scollo, P. Impact of recurrence of ovarian cancer on quality of life and outlook for the future. Int. J. Gynecol. Cancer 27, 1134\u20131140 (2017).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"21844_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/IGC.0000000000000843","volume":"27","author":"A Gadducci","year":"2017","unstructured":"Gadducci, A. et al. Patterns of recurrence and clinical outcome of patients with stage IIIC to stage IV epithelial ovarian cancer in complete response after primary debulking surgery plus chemotherapy or neoadjuvant chemotherapy followed by interval debulking surgery: An Italian multicenter retrospective study. Int. J. Gynecol. Cancer 27, 28\u201336 (2017).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"21844_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-017-0960-z","volume":"34","author":"B Oronsky","year":"2017","unstructured":"Oronsky, B. et al. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med. Oncol. 34, 103 (2017).","journal-title":"Med. Oncol."},{"key":"21844_CR9","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S1470-2045(11)70123-1","volume":"12","author":"SL Cooke","year":"2011","unstructured":"Cooke, S. L. & Brenton, J. D. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 12, 1169\u20131174 (2011).","journal-title":"Lancet Oncol."},{"key":"21844_CR10","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274\u20131284 (2017).","journal-title":"Lancet Oncol."},{"key":"21844_CR11","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda, A. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 620\u2013631 (2021).","journal-title":"Lancet Oncol."},{"key":"21844_CR12","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505 (2018).","journal-title":"N. Engl. J. Med."},{"key":"21844_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.21873\/anticanres.16202","volume":"43","author":"H Bourien","year":"2023","unstructured":"Bourien, H. et al. Real-world data on olaparib in relapsed BRCA-mutated ovarian cancer: A multicenter GINECO RETROLA cohort study. Anticancer Res. 43, 653\u2013662 (2023).","journal-title":"Anticancer Res."},{"key":"21844_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s12276-021-00557-3","volume":"53","author":"DS Kim","year":"2021","unstructured":"Kim, D. S., Camacho, C. V. & Kraus, W. L. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp. Mol. Med. 53, 42\u201351 (2021).","journal-title":"Exp. Mol. Med."},{"key":"21844_CR15","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","volume":"29","author":"SM Noordermeer","year":"2019","unstructured":"Noordermeer, S. M. & van Attikum, H. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol. 29, 820\u2013834 (2019).","journal-title":"Trends Cell Biol."},{"key":"21844_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","volume":"34","author":"D Slade","year":"2020","unstructured":"Slade, D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 34, 360\u2013394 (2020).","journal-title":"Genes Dev."},{"key":"21844_CR17","first-page":"1818","volume":"58","author":"S Darabi","year":"2022","unstructured":"Darabi, S. et al. BRCA1\/2 reversion mutations in patients treated with poly ADP-ribose polymerase (PARP) inhibitors or platinum agents. Med. Kaunas 58, 1818 (2022).","journal-title":"Med. Kaunas"},{"key":"21844_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/jnci\/djw148","volume":"108","author":"P Ter Brugge","year":"2016","unstructured":"Ter Brugge, P. et al. Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer. J. Natl. Cancer Inst. 108, 148 (2016).","journal-title":"J. Natl. Cancer Inst."},{"key":"21844_CR19","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","volume":"23","author":"B Weigelt","year":"2017","unstructured":"Weigelt, B. et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin. Cancer Res. 23, 6708\u20136720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"21844_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41586-018-0670-5","volume":"563","author":"YJ He","year":"2018","unstructured":"He, Y. J. et al. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature 563, 522\u2013526 (2018).","journal-title":"Nature"},{"key":"21844_CR21","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","volume":"9","author":"SJ Pettitt","year":"2018","unstructured":"Pettitt, S. J. et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat. Commun. 9, 1849 (2018).","journal-title":"Nat. Commun."},{"key":"21844_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188633","volume":"1876","author":"L Biegala","year":"2021","unstructured":"Biegala, L., Gajek, A., Marczak, A. & Rogalska, A. PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR\/CHK1 pathway. Biochim. Biophys. Acta Rev. Cancer 1876, 188633 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"21844_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110204","volume":"127","author":"H Xie","year":"2020","unstructured":"Xie, H., Wang, W., Xia, B., Jin, W. & Lou, G. Therapeutic applications of PARP inhibitors in ovarian cancer. Biomed. Pharmacother. 127, 110204 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"21844_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev-biochem-060713-035428","volume":"83","author":"DL Croteau","year":"2014","unstructured":"Croteau, D. L., Popuri, V., Opresko, P. L. & Bohr, V. A. Human RecQ helicases in DNA repair, recombination, and replication. Annu. Rev. Biochem. 83, 519\u2013552 (2014).","journal-title":"Annu. Rev. Biochem."},{"key":"21844_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1042\/BJ20060450","volume":"398","author":"S Sharma","year":"2006","unstructured":"Sharma, S., Doherty, K. M. & Brosh, R. M. Mechanisms of RecQ helicases in pathways of DNA metabolism and maintenance of genomic stability. Biochem. J. 398, 319\u2013337 (2006).","journal-title":"Biochem. J."},{"key":"21844_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nrc3560","volume":"13","author":"RM Brosh","year":"2013","unstructured":"Brosh, R. M. DNA helicases involved in DNA repair and their roles in cancer. Nat. Rev. Cancer 13, 542\u2013558 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"21844_CR27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/genes11060622","volume":"11","author":"S Debnath","year":"2020","unstructured":"Debnath, S. & Sharma, S. RECQ1 helicase in genomic stability and cancer. Genes 11, 622 (2020).","journal-title":"Genes"},{"key":"21844_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072820","volume":"8","author":"S Sanada","year":"2013","unstructured":"Sanada, S. et al. RECQL1 DNA repair helicase: A potential therapeutic target and a proliferative marker against ovarian cancer. PLoS ONE 8, e72820 (2013).","journal-title":"PLoS ONE"},{"key":"21844_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13048-014-0107-1","volume":"7","author":"Y Matsushita","year":"2014","unstructured":"Matsushita, Y. et al. The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer. J. Ovarian Res. 7, 107 (2014).","journal-title":"J. Ovarian Res."},{"key":"21844_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/1535-7163.MCT-16-0290","volume":"16","author":"A Arora","year":"2017","unstructured":"Arora, A. et al. Clinicopathological and functional significance of RECQL1 helicase in sporadic breast cancers. Mol. Cancer Ther. 16, 239\u2013250 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"21844_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1476-4598-10-83","volume":"10","author":"R Mendoza-Maldonado","year":"2011","unstructured":"Mendoza-Maldonado, R. et al. The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation. Mol. Cancer 10, 83 (2011).","journal-title":"Mol. Cancer"},{"key":"21844_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001297","volume":"2","author":"S Sharma","year":"2007","unstructured":"Sharma, S. & Brosh, R. M. Jr. Human RECQ1 is a DNA damage responsive protein required for genotoxic stress resistance and suppression of sister chromatid exchanges. PLoS ONE 2, e1297 (2007).","journal-title":"PLoS ONE"},{"key":"21844_CR33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nsmb.2501","volume":"20","author":"M Berti","year":"2013","unstructured":"Berti, M. et al. Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition. Nat. Struct. Mol. Biol. 20, 347\u2013354 (2013).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"21844_CR34","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.15252\/embj.201694920","volume":"36","author":"J Woodrick","year":"2017","unstructured":"Woodrick, J. et al. A new sub-pathway of long-patch base excision repair involving 5\u2019 gap formation. EMBO J. 36, 1605\u20131622 (2017).","journal-title":"EMBO J."},{"key":"21844_CR35","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/leu.2017.54","volume":"31","author":"E Viziteu","year":"2017","unstructured":"Viziteu, E. et al. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Leukemia 31, 2104\u20132113 (2017).","journal-title":"Leukemia"},{"key":"21844_CR36","doi-asserted-by":"publisher","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","volume":"65","author":"RS Bindra","year":"2005","unstructured":"Bindra, R. S. et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 65, 11597\u201311604 (2005).","journal-title":"Cancer Res."},{"key":"21844_CR37","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416\u20132428 (2019).","journal-title":"N. Engl. J. Med."},{"key":"21844_CR38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ygyno.2014.03.007","volume":"133","author":"PA Konstantinopoulos","year":"2014","unstructured":"Konstantinopoulos, P. A., Wilson, A. J., Saskowski, J., Wass, E. & Khabele, D. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol. Oncol. 133, 599\u2013606 (2014).","journal-title":"Gynecol. Oncol."},{"key":"21844_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3390\/diagnostics10020121","volume":"10","author":"BT Burgess","year":"2020","unstructured":"Burgess, B. T. et al. Olaparib combined with an ATR or Chk1 inhibitor as a treatment strategy for acquired olaparib-resistant BRCA1 mutant ovarian cells. Diagnostics 10, 121 (2020).","journal-title":"Diagnostics"},{"key":"21844_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","volume":"71","author":"B Haynes","year":"2018","unstructured":"Haynes, B., Murai, J. & Lee, J. M. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat. Rev. 71, 1\u20137 (2018).","journal-title":"Cancer Treat. Rev."},{"issue":"15 suppl","key":"21844_CR41","first-page":"65","volume":"39","author":"SN Westin","year":"2021","unstructured":"Westin, S. N. et al. EFFORT: Efficacy of adavosertib in PARP resistance: A randomized 2-arm non-comparative phase 2 study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer [ASCO abstract 5505]. J. Clin. Oncol. 39(15 suppl), 65 (2021).","journal-title":"J. Clin. Oncol."},{"key":"21844_CR42","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1158\/1078-0432.CCR-21-1279","volume":"27","author":"KT Do","year":"2021","unstructured":"Do, K. T. et al. Phase 1 combination study of the CHK1 inhibitor prexasertib and the PARP inhibitor olaparib in high-grade serous ovarian cancer and other solid tumors. Clin. Cancer Res. 27, 4710\u20134716 (2021).","journal-title":"Clin. Cancer Res."},{"key":"21844_CR43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.neo.2020.06.009","volume":"22","author":"Y Xiong","year":"2020","unstructured":"Xiong, Y. et al. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia 22, 431\u2013440 (2020).","journal-title":"Neoplasia"},{"key":"21844_CR44","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","volume":"23","author":"S Lheureux","year":"2017","unstructured":"Lheureux, S. et al. Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization. Clin. Cancer Res. 23, 4086\u20134094 (2017).","journal-title":"Clin. Cancer Res."},{"key":"21844_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7149","volume":"13","author":"R Uekusa","year":"2024","unstructured":"Uekusa, R. et al. Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer. Cancer Med. 13, e7149 (2024).","journal-title":"Cancer Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21844-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21844-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21844-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T15:04:26Z","timestamp":1761836666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21844-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21844"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21844-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Saitama Medical University International Medical Center (reference number: 2022-112). This study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"38089"}}